GGrantIndex
← Leaderboards

Matthew J Ellis

Duke University

Google Scholar ↗PubMed ↗ORCID ↗
$25,349,408
Attributed
$39,128,086
Total exposure
15
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.3M · FY2005–24
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$41,265,916 · 16

By mechanism

U01$14,316,893 · 2
U24$11,820,855 · 1
R01$5,571,771 · 1
P50$4,105,740 · 4
U10$2,590,746 · 1
U54$1,898,211 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Breast Neoplasm”

Research focus

Malignant Breast NeoplasmTumorSamplingProgramsBaseDiagnosisClinical TrialsMolecularResponseDiagnosticMutationTechnologyInvestigationNeoadjuvant TherapyGenomicsProteomicsResearch PersonnelGene ExpressionPatternGenomeClinical PracticeMass Spectrum AnalysisGenesMalignant Neoplasms

Grant awards (55)

Project 1: Co-Targeting ER and Kinome Deregulation in Breast Cancers with Neurofibromin Deficiency$269,620
P50 · FY2024 · CA · contact PI
Administration and Advocacy$148,271
P50 · FY2024 · CA · contact PI
Project 1: Co-Targeting ER and Kinome Deregulation in Breast Cancers with Neurofibromin Deficiency$330,481
P50 · FY2023 · CA · contact PI
Administration and Advocacy$181,002
P50 · FY2023 · CA · contact PI
Project 1: Co-Targeting ER and Kinome Deregulation in Breast Cancers with Neurofibromin Deficiency$339,831
P50 · FY2022 · CA · contact PI
Administration and Advocacy$174,945
P50 · FY2022 · CA · contact PI
Translational Research in Breast Cancer$2,137,830
P50 · FY2020 · CA · contact PI
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS$1,403,852
U01 · FY2020 · CA · contact PI
Project 1: Co-Targeting ER and Kinome Deregulation in Breast Cancers with Neurofibromin Deficiency$338,869
P50 · FY2020 · CA · contact PI
Translational Breast Cancer Research Training Program$211,871
T32 · FY2020 · CA
Administration and Advocacy$184,891
P50 · FY2020 · CA · contact PI
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS$1,351,343
U01 · FY2019 · CA · contact PI
Translational Breast Cancer Research Training Program$202,856
T32 · FY2019 · CA
RP2: Targeting Estrogen receptor and DNA damage repair disparities in African American and Hispanic/Latino breast cancer using Patient-Derived Breast Cancer Xenografts$1,898,211
U54 · FY2018 · CA · contact PI
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS$1,413,657
U01 · FY2018 · CA · contact PI
Integrated Translational Genoproteomics Center at Washington University$451,509
U10 · FY2018 · CA
Translational Breast Cancer Research Training Program$194,523
T32 · FY2018 · CA
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS$1,452,478
U01 · FY2017 · CA · contact PI
Integrated Translational Genoproteomics Center at Washington University$540,405
U10 · FY2017 · CA
Cancer Proteome Center at Washington Univ, Univ of North Carolina$849,998
U24 · FY2016 · CA
Integrated Translational Genoproteomics Center at Washington University$428,007
U10 · FY2016 · CA
Cancer Proteome Center at Washington Univ, Univ of North Carolina$2,267,206
U24 · FY2015 · CA
Integrated Translational Genoproteomics Center at Washington University$570,826
U10 · FY2015 · CA
Cancer Proteome Center at Washington Univ, Univ of North Carolina$2,197,655
U24 · FY2014 · CA
Integrated Translational Genoproteomics Center at Washington University$599,999
U10 · FY2014 · CA
Breast Cancer Research$61,003
P30 · FY2014 · CA · contact PI
Cancer Proteome Center at Washington Univ, Univ of North Carolina$2,120,962
U24 · FY2013 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$506,879
R01 · FY2013 · CA
Breast Cancer Research$60,201
P30 · FY2013 · CA · contact PI
Cancer Proteome Center at Washington Univ, Univ of North Carolina & Boise State$2,185,560
U24 · FY2012 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$541,108
R01 · FY2012 · CA · contact PI
Breast Cancer Research$62,815
P30 · FY2012 · CA · contact PI
Breast Cancer Research$2,778
P30 · FY2012 · CA · contact PI
Cancer Proteome Center at Washington Univ, Univ of North Carolina & Boise State$2,199,474
U24 · FY2011 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$543,089
R01 · FY2011 · CA · contact PI
PROTEOGENOMIC ANALYSIS OF HUMAN-IN-MOUSE BREAST CANCER XENOGRAFTS$14,391
P41 · FY2011 · RR · contact PI
Breast Cancer Research$7,481
P30 · FY2011 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$562,544
R01 · FY2010 · CA · contact PI
Breast Cancer Research$7,865
P30 · FY2010 · CA · contact PI
Biological Breast Cancer Classification by qRT-PCR$1,707,248
U01 · FY2009 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$551,616
R01 · FY2009 · CA · contact PI
Biological Breast Cancer Classification by qRT-PCR$496,022
U01 · FY2009 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$5,825
P41 · FY2009 · RR · contact PI
Biological Breast Cancer Classification by qRT-PCR$1,675,239
U01 · FY2008 · CA · contact PI
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY$8,137
P41 · FY2008 · RR · contact PI
Biological Breast Cancer Classification by qRT-PCR$1,549,377
U01 · FY2007 · CA · contact PI
Novel Biomarkers for Aromatase Inhibitor Therapy$444,980
R01 · FY2007 · CA · contact PI
Biological Breast Cancer Classification by qRT-PCR$1,549,177
U01 · FY2006 · CA · contact PI
Novel Biomarkers for Aromatase Inhibitor Therapy$511,683
R01 · FY2006 · CA · contact PI
Biological Breast Cancer Classification by qRT-PCR$1,718,500
U01 · FY2005 · CA
Novel Biomarkers for Aromatase Inhibitor Therapy$650,984
R01 · FY2005 · CA
Novel Biomarkers for Aromatase Inhibitor Therapy$637,708
R01 · FY2004 · CA
Novel Biomarkers for Aromatase Inhibitor Therapy$621,180
R01 · FY2003 · CA
NEGATIVE REGULATION OF IGF-11 BY THE IGF-11R IN CANCER$63,602
R29 · FY2000 · CA
NEGATIVE REGULATION OF IGF-11 BY THE IGF-11R IN CANCER$58,352
R29 · FY2000 · CA